CSF2: Granulocyte-macrophage colony-stimulating factor
Cytokine that stimulates the growth and differentiation of hematopoietic precursor cells from various lineages, including granulocytes, macrophages, eosinophils and erythrocytes. .
- Drugs that act on it: 6
- Approved: 0
- In phases 1 to 3: 6
- Sponsors: 6
Who is on it, and how far along
Every drug ChEMBL records acting on CSF2, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 5
- Other 1
Approved0
Phase 33
Phase 23
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- GSK117%
- Humanigen, Inc.117%
- Jennerex Biotherapeutics117%
- Kinevant Sciences GmbH117%
- Takeda Pharmaceuticals USA117%
- TJ Biopharma Co., Ltd.117%
| Lenzilumab | Phase 3 | Humanigen, Inc. | Antibody | Inhibitor | 0 |
| Otilimab | Phase 3 | GSK | Antibody | Inhibitor | 0 |
| Pexastimogene devacirepvec | Phase 3 | Jennerex Biotherapeutics | Gene | Vaccine antigenGranulocyte-macrophage colony-stimulating factor vaccine antigen | 0 |
| Plonmarlimab | Phase 2 | TJ Biopharma Co., Ltd. | Antibody | AntagonistGranulocyte-macrophage colony-stimulating factor antagonist | 2 |
| Gimsilumab | Phase 2 | Kinevant Sciences GmbH | Antibody | Inhibitor | 0 |
| Namilumab | Phase 2 | Takeda Pharmaceuticals USA | Antibody | Inhibitor | 0 |
| A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthritis | Plonmarlimab | Phase 2 | Recruiting | TJ Biopharma Co., Ltd. | Mar 5, 2026 |
| A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS]) | Plonmarlimab | Phase 3 | Recruiting | TJ Biopharma Co., Ltd. | Oct 6, 2025 |
- Asthma0.53
- Rheumatoid arthritis0.41
- Hepatocellular carcinoma0.36
- COVID-190.35
- Hypothyroidism0.34
- Psoriasis0.31
- Neurodegenerative disease0.29
- Atopic eczema0.28
- Dermatitis0.24
- Nasal cavity polyp0.21
- Lower respiratory tract disorder0.19
- Myocardial infarction0.15
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712955, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P04141, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets